RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer: Robert NJ, Diéras V, Glaspy J, et al (Virginia Cancer Specialists, Fairfax; Univ of California, Los Angeles; Genentech, South San Francisco, CA; et al) J Clin Oncol 29:1252-1260, 2011 §